tetano
Editor, Senior Moderator
J Med Virol. 2016 Oct 21. doi: 10.1002/jmv.24717. [Epub ahead of print]
[h=1]Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model.[/h] Don ES[SUP]1[/SUP], Emelyanova AG[SUP]2[/SUP], Yakovleva NN[SUP]3[/SUP], Petrova NV[SUP]2[/SUP], Nikiforova MV[SUP]3[/SUP], Gorbunov EA[SUP]3[/SUP], Tarasov SA[SUP]3[/SUP], Morozov SG[SUP]2[/SUP], Epstein OI[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The assessment of dose-response is an essential part of drug development in terms of the determination of a drug's effective dose, finding the safety endpoint, estimation of the pharmacokinetic profile and even validation of drug activity, especially for therapeutic agents with a principally novel mechanism of action. Drugs based on released-active forms of antibodies are a good example of such a target. In this study, the efficacy of the antiviral drug Anaferon for children (released-active form of antibodies to interferon-gamma) was tested in a dose-dependent manner (at doses of 0.13; 0.2; 0.4; 0.8 ml/mouse/day) in a murine model of acute pneumonia induced by influenza virus pandemic strain A/California/07/09 (H1N1). Administration of the drug at the two highest doses led to: a reduction in the virus infectious titer in lung tissue up to 4.2lgEID50/20 mg of tissue; infected animals' life prolongation up to 6.7 days; an increase in the survival rate of up to 40% and a decrease in morphological signs of inflammation when compared to the control animals. In this study, the dose-response effect of Anaferon for Children was demonstrated on mice for the first time. This finding is especially important for drugs with a principally novel mechanism of action like drugs based on released-active forms of antibodies. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] Animal models of infection < Research and Analysis Methods; Antibody-containing preparations < Disease control; Antiviral agents < Disease control; Influenza virus < Virus classification
PMID: 27769099 DOI: 10.1002/jmv.24717
[PubMed - as supplied by publisher]
[h=1]Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model.[/h] Don ES[SUP]1[/SUP], Emelyanova AG[SUP]2[/SUP], Yakovleva NN[SUP]3[/SUP], Petrova NV[SUP]2[/SUP], Nikiforova MV[SUP]3[/SUP], Gorbunov EA[SUP]3[/SUP], Tarasov SA[SUP]3[/SUP], Morozov SG[SUP]2[/SUP], Epstein OI[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The assessment of dose-response is an essential part of drug development in terms of the determination of a drug's effective dose, finding the safety endpoint, estimation of the pharmacokinetic profile and even validation of drug activity, especially for therapeutic agents with a principally novel mechanism of action. Drugs based on released-active forms of antibodies are a good example of such a target. In this study, the efficacy of the antiviral drug Anaferon for children (released-active form of antibodies to interferon-gamma) was tested in a dose-dependent manner (at doses of 0.13; 0.2; 0.4; 0.8 ml/mouse/day) in a murine model of acute pneumonia induced by influenza virus pandemic strain A/California/07/09 (H1N1). Administration of the drug at the two highest doses led to: a reduction in the virus infectious titer in lung tissue up to 4.2lgEID50/20 mg of tissue; infected animals' life prolongation up to 6.7 days; an increase in the survival rate of up to 40% and a decrease in morphological signs of inflammation when compared to the control animals. In this study, the dose-response effect of Anaferon for Children was demonstrated on mice for the first time. This finding is especially important for drugs with a principally novel mechanism of action like drugs based on released-active forms of antibodies. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] Animal models of infection < Research and Analysis Methods; Antibody-containing preparations < Disease control; Antiviral agents < Disease control; Influenza virus < Virus classification
PMID: 27769099 DOI: 10.1002/jmv.24717
[PubMed - as supplied by publisher]